I completely agree Sanchez. You mention only the syringe which has huge prospects. Braun has estimated income in Australia alone over next 5 years somewhere around 10 - 12 million for SCALPAL alone, with sales all over the world on top of this.
Don'[t be fooled by low volume over last day or 2 - It just shows that there is B**** A** selling in this consolidation phase.
Buying will return with avengence. With shares in escrow only 25 million in total - I think we do have another cochlier at least.
Technically I really can't see it closing below 2.76
ICU Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
